Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.47 |
| ▸ | DRD3 | P35462 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | DRD1 | P21728 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | GRM5 | P41594 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL274434 | 1.00 | DRD2 (0.47) | DRD2DRD3LMNADRD1MEN1 | |
| SCHEMBL9824110 | 1.00 | DRD2 (0.47) | DRD2DRD3LMNADRD1MEN1 | |
| SCHEMBL31346795 | 1.00 | DRD2 (0.47) | DRD2DRD3LMNADRD1MEN1 | |
| SCHEMBL9824113 | 1.00 | DRD2 (0.47) | DRD2DRD3LMNADRD1MEN1 | |
| SCHEMBL31346794 | 1.00 | DRD2 (0.47) | DRD2DRD3LMNADRD1MEN1 | |
| SCHEMBL7272577 | 0.89 | DRD2 (0.49) | DRD2DRD3LMNADRD1MEN1 | |
| SCHEMBL10840848 | 0.89 | DRD2 (0.49) | DRD2DRD3LMNADRD1MEN1 | |
| SCHEMBL4959151 | 0.89 | DRD2 (0.49) | DRD2DRD3LMNADRD1MEN1 | |
| SCHEMBL7272572 | 0.89 | DRD2 (0.49) | DRD2DRD3LMNADRD1MEN1 | |
| SCHEMBL5998568 | 0.89 | DRD2 (0.49) | DRD2DRD3LMNADRD1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE43244-E1 | Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use | H. LUNDBECK A/S (DK) | 2012-03-13 | — | — | US | disclosed |
| US-RE42802-E1 | Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use | H. LUNDBECK A/S (DK) | 2011-10-04 | — | — | US | disclosed |
| US-6998405-B2 | Parkinson's and Huntington's disease; psychoses, impotence, renal or heart failure, schizophrenia | H. LUNDBECK A/S (DK) | 2006-02-14 | — | — | US | disclosed |
| EP-1274411-B1 | PHENYLETHYLAMINES AND CONDENSED RINGS VARIANTS AS PRODRUGS OF CATECHOLAMINES, AND THEIR USE | LUNDBECK & CO AS H (DK) | 2005-07-27 | — | — | EP | disclosed |
| US-20040138281-A1 | Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use | AXON BIOCHEMICALS B.V. (NL) | 2004-07-15 | — | — | US | disclosed |
| US-6683087-B2 | TREATMENT OF PARKINSON'S DISEASE, PSYCHOSES, HUNTINGTON'S DISEASE, IMPOTENCE, RENAL FAILURE, HEART FAILURE OR HYPERTENSION | AXON BIOCHEMICALS B.V. (NL) | 2004-01-27 | — | — | US | disclosed |
| US-20030087948-A1 | Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use | H. LUNDBECK A/S (DK) | 2003-05-08 | — | — | US | disclosed |
| EP-0172697-B1 | Octahydro-oxazolo[4,5-g]quinolines | ELI LILLY AND COMPANY (US) | 1991-09-25 | — | — | EP | disclosed |
| US-4698347-A | HYPOTENSIVE AGENTS, ANTIDEPRESSANTS, SEXUAL DISFUNCTION, PARKINSONS DISEASE | ELI LILLY AND COMPANY (US) | 1987-10-06 | — | — | US | disclosed |
| US-4659832-A | REACTING UREA (OR ISOUREA) WITH 6-OXO-BROMO-QUINOLINE | ELI LILLY AND COMPANY (US) | 1987-04-21 | — | — | US | disclosed |
| US-4647667-A | Octa- and deca-hydroquinoline intermediates | ELI LILLY AND COMPANY (US) | 1987-03-03 | — | — | US | disclosed |
| US-4600777-A | Method of preparing 1-alkyl-7-oxodecahydroquinolines, and cis(±) and tran(±)isomers so prepared | ELI LILLY AND COMPANY (US) | 1986-07-15 | — | — | US | disclosed |
| EP-0172697-A2 | Octahydro-oxazolo[4,5-g]quinolines | ELI LILLY AND COMPANY (US) | 1986-02-26 | — | — | EP | disclosed |
| US-4567266-A | Method of preparing octahydro-1H(and 2H)-pyrazolo[3,4-g]quinolines | ELI LILLY AND COMPANY (US) | 1986-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138281-A1 | Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use | ADRA1D, ABCE1, ADRA1B | DRD2 9/4885DRD3 18/4885LMNA 1865/4885 |
| US-20030087948-A1 | Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use | ADRA1D, ABCE1, ADRA1B | DRD2 9/4885DRD3 18/4885LMNA 1884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.